PURPOSE: In a longitudinal observation, extravasation of antitumoural compounds and the efficacy of its structured interdisciplinary management were assessed in a routine setting. METHODS: One hundred sixty-nine patients with extravasation of cytotoxics were managed according to a prospective approach documenting the extravasated compound, localisation, duration until full symptom resolution and sequelae. Surgery was implemented in the case of failure of conservative measures. RESULTS: In 155 (91.7 %) out of 169 patients, conservative management was successful (surgical intervention, 14 patients). Extravasations of anthracyclines (N = 44), platinum compounds (N = 41), vinca alkaloids (N = 20) and taxanes (N = 19) were often associated with erythema, oedema and pain. The median period until full resolution of symptoms differed among the administered cytotoxics (anthracyclines, 55 days; taxanes and vinca alkaloids, 27 days; platinum compounds, 14 days) with statistical significance between the vesicants. Histologically, surgically resected specimens showed extensive necrotic areas with inflammatory infiltrates at the periphery of the removed lesions. CONCLUSIONS: In a routine setting, the standardised management of cytotoxic extravasations by an interdisciplinary task force resulted in a satisfactory outcome. When surgical intervention was indicated, complete remission of the lesions within a median of 14 days reduced the delay in the administration of further chemotherapy to a minimum. The proposed approach is therefore considered as suitable to manage extravasations in cancer chemotherapy in a large number of subjects and to ensure patient adherence to cytotoxic treatment.
PURPOSE: In a longitudinal observation, extravasation of antitumoural compounds and the efficacy of its structured interdisciplinary management were assessed in a routine setting. METHODS: One hundred sixty-nine patients with extravasation of cytotoxics were managed according to a prospective approach documenting the extravasated compound, localisation, duration until full symptom resolution and sequelae. Surgery was implemented in the case of failure of conservative measures. RESULTS: In 155 (91.7 %) out of 169 patients, conservative management was successful (surgical intervention, 14 patients). Extravasations of anthracyclines (N = 44), platinum compounds (N = 41), vinca alkaloids (N = 20) and taxanes (N = 19) were often associated with erythema, oedema and pain. The median period until full resolution of symptoms differed among the administered cytotoxics (anthracyclines, 55 days; taxanes and vinca alkaloids, 27 days; platinum compounds, 14 days) with statistical significance between the vesicants. Histologically, surgically resected specimens showed extensive necrotic areas with inflammatory infiltrates at the periphery of the removed lesions. CONCLUSIONS: In a routine setting, the standardised management of cytotoxic extravasations by an interdisciplinary task force resulted in a satisfactory outcome. When surgical intervention was indicated, complete remission of the lesions within a median of 14 days reduced the delay in the administration of further chemotherapy to a minimum. The proposed approach is therefore considered as suitable to manage extravasations in cancer chemotherapy in a large number of subjects and to ensure patient adherence to cytotoxic treatment.
Authors: Todd A Theman; Tristan L Hartzell; Indranil Sinha; Kathleen Polson; Jeffrey Morgan; George D Demetri; Dennis P Orgill; Suzanne George Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: H T Mouridsen; S W Langer; J Buter; H Eidtmann; G Rosti; M de Wit; P Knoblauch; A Rasmussen; K Dahlstrøm; P B Jensen; G Giaccone Journal: Ann Oncol Date: 2006-12-21 Impact factor: 32.976
Authors: G Bertelli; D Dini; G B Forno; A Gozza; S Silvestro; M Venturini; R Rosso; P Pronzato Journal: J Cancer Res Clin Oncol Date: 1994 Impact factor: 4.553
Authors: Werner Haslik; Ursula Pluschnig; Günther G Steger; Christoph C Zielinski; K F Schrögendorfer; Jakob Nedomansky; Rupert Bartsch; Robert M Mader Journal: PLoS One Date: 2014-08-21 Impact factor: 3.240
Authors: Jakob Nedomansky; Werner Haslik; Ursula Pluschnig; Christoph Kornauth; Christine Deutschmann; Stefan Hacker; Günther G Steger; Rupert Bartsch; Robert M Mader Journal: Cancer Chemother Pharmacol Date: 2021-04-27 Impact factor: 3.333
Authors: Nicolai Kapalschinski; Ole Goertz; Kamran Harati; Maximilian Kueckelhaus; Jonas Kolbenschlag; Marcus Lehnhardt; Tobias Hirsch Journal: Front Oncol Date: 2015-12-01 Impact factor: 6.244